37 results about "Mucosal vaccine" patented technology

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

Hydration of a larynx and / or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and / or NaCl) can achieve prophylactic and / or therapeutic effects (e.g., cough suppression, improving voice quality, increasing pulse oxygen saturation and / or increasing mucosal vaccination effectiveness). The composition is administered as dry particles (e.g., aerosol) or as a liquid (e.g., solution, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 μm to approximately 15 μm or from approximately 15 μm to approximately 500 μm. A therapeutic dose (e.g., 0.5 mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.

Methods for stabilizing a liquid vaccine for mucosal use are provided. In certain aspects, the methods may include combining a liquid comprising at least one antigen or antigen encoding composition with a petrolatum carrier.

This invention discloses a method for rapidly constructing a complex of cholera toxin B subunit (CTB) and antigen. The vaccine complex includes a CTB-SpyTag fusion protein and at least one SpyCatcher-antigen fusion protein. It also includes a preparation method for rapidly preparing a CTB5-antigen complex by mixing CTB-SpyTag with the SpyCatcher-antigen. This invention directs the antigen to the side of the CTB pentamer that does not participate in GM1 binding, avoiding steric hindrance interference. It utilizes the SpyTag / SpyCatcher covalent isopeptide bond to obtain highly stable antigen display, reducing antigen shedding during subsequent preparation and storage. It also possesses mucosal targeting and multivalent presentation functions, providing a universal platform technology for rapidly constructing and validating broad-spectrum, combined, or personalized mucosal vaccines.

The present invention relates to novel peptides, compositions and uses thereof in tissue penetration, in particular in the context of cancer prevention and / or treatment or induction of an immune response, in particular mucosal vaccination or anti-opioid treatment.

The present invention relates to a vaccine composition for mucosal immunity and use thereof. It has been identified that the vaccine composition of the present invention is in the form of a 2D patch and effectively induces nasal mucosal immunity despite nasal mucociliary clearance (MCC). Thus, the vaccine composition provided in the present invention can be variously utilized for mucosal immunity in which various antigenic substances are used.

The invention provides a nano vaccine vector based on cholesteroid-free capsule protein and application of the nano vaccine vector, and belongs to the technical field of nano particle vaccines. The nano vaccine carrier is formed by sequentially connecting cholesteroid-free capsule protein, extension peptide, linker and molecular glue from an N end to a C end. The invention also provides a nano vaccine based on the cholesteric plasma-free capsule protein. The antigen is obtained by reacting the carrier with an antigen connected with SpyTag, SpyTag002 or SpyTag003. The invention also provides a mycoplasma hyopneumoniae nano vaccine and a new crown nano vaccine. The antigen is obtained by reacting the carrier with an antigen connected with SpyTag003. The nano vaccine vector disclosed by the invention can be used for intramuscular injection vaccines and mucosal vaccines for human and livestock, can remarkably improve the immune effect and enhance the immune response while displaying antigens, has a remarkable self-adjuvant effect, and provides a safe and efficient potential choice for the development of subunit vaccines.

Provided is an adjuvant for mucosal vaccines comprising a sulfated archaeosome comprising a sulfated glycoarchaeol. The glycoarchaeol may be present as a pharmaceutically acceptable salt. The adjuvant

Disclosed in the present invention are a fatty acid-modified coronavirus antigen and use thereof, pertaining to the field of biomedicine. The fatty acid-modified coronavirus antigen comprises a fatty acid-modified N-terminal cysteine (Cys) and a coronavirus antigen, and may comprise a linking domain. The coronavirus antigen is a coronavirus spike protein (S protein) receptor-binding domain (RBD). The fatty acid-modified coronavirus S protein RBD can self-assemble into nanoparticles. Compared with an RBD without fatty acid modification, the antigen can induce faster and higher humoral immunity by means of injection immunization, and can also induce mucosal immunity and humoral immunity by means of respiratory nebulization immunization, making it a candidate mucosal vaccine with potential medical value.

The invention belongs to the technical field of medicines, and particularly relates to a vaccine preparation strategy taking new coronavirus spike protein as a respiratory mucosa vaccine antigen protein carrier, which is used for preventing respiratory pathogen infection. The novel coronavirus spike protein has good potential as a respiratory mucosa vaccine antigen vector, and can be used for enhancing mucosa and system immune response aiming at a target pathogen.

Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-CoV-2 or at risk of being exposed to SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.

The invention provides recombinant lactobacillus plantarum for expressing porcine epidemic diarrhea virus S1 protein as well as a preparation method and application of the recombinant lactobacillus plantarum, and belongs to the technical field of preparation of porcine epidemic diarrhea virus vaccines. The recombinant lactobacillus plantarum provided by the invention contains a recombinant vector for expressing a PEDV tS1 fusion gene, and the PEDV tS1 fusion gene comprises a PEDV tS1 structural domain, an endogenous signal peptide 1320 and a dendritic cell targeting peptide DCpep. After the recombinant lactobacillus plantarum provided by the invention is used as a mucosal vaccine through nasal dripping, not only can a codon be prevented from being repeatedly optimized, but also strong cross-species immune response can be induced, pathogen specificity sIgA can be generated, mucosal immunity can be effectively activated, and the induced antibody has the activity of neutralizing PEDV (porcine epidemic diarrhea virus). The recombinant lactobacillus plantarum provided by the invention has a treatment effect.

The invention relates to a SpaCBA-OVA liposome nanoparticle as well as a preparation method and application thereof. The SpaCBA-OVA liposome nanoparticle is formed by encapsulating SpaCBA and OVA in a liposome together, according to the SpaCBA-OVA lipidosome nanoparticles subjected to engineering modification, SpaCBA and OVA are jointly encapsulated in the lipidosome, so that continuous antigen release is given to encapsulated protein, and the limitation of mucosal vaccines is solved; through double receptor uptake, allergen presentation and immunomodulatory signal transduction are balanced, and the release of the dendritic cell immunomodulatory factor IL-10 / TGF-beta is enhanced, so that the problems proposed in the background technology can be well solved.

The application belongs to the technical field of biological medicine, and discloses a microneedle patch vaccine for inducing mucosal immune response and a preparation method and application thereof, specifically discloses a novel vaccine for inducing mucosal immune response, and the vaccine is delivered by a microneedle patch.The DNA nanoparticles wrapped by chitosan oligosaccharide are creatively combined with the microneedle technology, and it is proved that the strategy can induce a strong antigen-specific immune response in mucosal tissues such as lungs.The technology can be universally applied to the development of a novel mucosal vaccine for preventing mucosal route infectious pathogens (such as new coronavirus).

Among the various aspects of the present disclosure is the provision of a coronavirus vaccine and methods of making and using the same. The vaccine composition includes a nucleic acid encoding at least a portion of the genome of an adenovirus; and at least a portion of at least one phylogenetically inferred receptor binding domain (RBD) sequence from a Sarbecovirus clade or an immunogenic portion, variant, mutant, or fragment thereof.

This invention discloses a rice codon-optimized SARS-CoV-2 Omicron mutant receptor-binding domain dimer protein gene and its applications. The OdiRBD gene consists of two RBD sequences linked by a flexible peptide. Transgenic rice is pulverized and mixed with extraction buffer, then subjected to ultrasonic lysis followed by further extraction and filtration to obtain a crude extract containing OdiRBD. The crude extract containing OdiRBD is then subjected to nickel column chromatography to obtain purified OdiRBD. This method yields plants with stable expression, high extraction efficiency, and is suitable for large-scale production. The rice-derived OdiRBD purified by this method can effectively induce humoral, mucosal, and cellular immune responses in mice via intranasal immunization, and can be used for the development of rice-expressed mucosal vaccines, showing promising application prospects.

The invention discloses a novel coronal virus mucosal immune vaccine based on a non-replicating vesicular stomatitis virus vector. The vaccine is delivered through a mucosal immunization way; the vaccine can be used in new crown vaccines, and can also be used in combination with other respiratory tract infection viruses such as respiratory syncytial vaccines (RSV) and influenza. At present, preparation of respiratory mucosa vaccines, especially multivalent vaccines, from replication-deficient VSV is not reported yet. According to the invention, safety and immunogenicity evaluation is carried out on the constructed VSVMT-S2P non-replicating recombinant VSV new crown vaccine in healthy narrative golden hamster and CP immunosuppression hamster models, and the VSVMT-S2P vaccine is found to be very safe in healthy animals; and the protein is highly safe in CP immunosuppressed hamsters. The VSVMT-S2P vaccine is subjected to single inoculation in the body of the narrative golden hamster through intranasal and intramuscular injection respectively, and it is proved that the VSVMT-S2P vaccine can effectively stimulate comprehensive immune response.

This invention relates to a mucosal vaccine composition and to an adjuvant comprising highly deacetylated chitosan for use in a method of immunotherapy, wherein the adjuvant is administered by a mucosal administration.

A non-infectious bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.

The invention relates to the field of biological medicine, in particular to a nucleic acid delivery carrier compound formula and application thereof, and the nucleic acid delivery carrier compound formula is prepared from the following components in parts by mole: 5 to 12 parts of HEDMA-Apd-C12, 31.3 to 41.3 parts of D-lin-MC3-DMA, 10 to 28.8 parts of auxiliary phospholipid, 19.2 to 42.7 parts of cholesterol and 1.5 to 2 parts of PEG conjugated lipid. According to the formula, mRNA expressed by efficient protein can be wrapped and used for treating related defect diseases, and specific transfection is achieved in a T cell and NK cell system of a serum-free culture system. Compared with a DLin-MC3-DMA assembled cationic liposome formula and an SM-102 assembled cationic liposome formula, the effect of the formula disclosed by the invention is improved. The research provides a novel efficient and low-toxicity delivery strategy for cell and gene therapy, especially serum-free system CAR-T manufacturing, mucosal vaccine development and the like.

Embodiments of the present disclosure generally relate to compositions of a lyophilized (freeze dried) Listeria strain based therapeutics and a method for lyophilizing compositions of the therapeutics. A Listeria monocytogenes (LM) based vaccine formulation contains a lyophilized powder including a LM bacteria, the LM bacteria comprising at least one therapeutic agent and a lyophilization medium and a delivery composition. A method of forming a Listeria monocytogenes (LM) based vaccine formulation is disclosed. The LM based vaccine formulation includes resuspending an LM stock in a lyophilization medium to form a lyophilization composition, wherein the lyophilization medium comprises at least a lyoprotectant and a buffer component, freezing the lyophilization composition, lyophilizing the lyophilization composition, and forming a lyophilized powder, the lyophilized powder contains a LM bacteria, a lyoprotectant, and a buffer component.

The application belongs to the field of immunology and relates to an mRNA delivery carrier, a preparation method and application of an oral vaccine. A calcium alginate microsphere and a cholic acid-fluorine co-modified polyethyleneimine (DFP) form a double protection system, the compact crosslinked structure of the calcium alginate microsphere resists the acid-base environment of the gastrointestinal tract and nuclease degradation, and the complex formed by the DFP and the mRNA can further prevent the mRNA from being enzymatically degraded. The application provides preparation of an oral mRNA delivery system for activating intestinal mucosal immunity and application of the oral mRNA delivery system in a diarrhea vaccine, provides effective protection against porcine diarrhea coronavirus infection, and provides a new idea for research and development of intestinal mucosal vaccines.

The invention relates to the technical field of medicines, and relates to application of carvedilol in preparation of a novel coronavirus respiratory mucosa vaccine. The novel coronavirus respiratory mucosa vaccine is a vaccine which takes carvedilol as a unique immunologic adjuvant or a composite adjuvant containing capsaicin and is inoculated through a nasal drop or nasal spray way to prevent novel coronavirus infection. The recombinant new coronavirus spike protein is used as an antigen and is mixed with carvedilol, and the mixture is inoculated to a narla golden hamster in a nasal drop manner. Experimental results show that carvedilol can effectively promote a body to generate a specific antibody aiming at spike protein, so that the IgG level in serum is remarkably improved, and IgA response in alveolar lavage fluid is also enhanced. Therefore, a basis is provided for development of carvedilol as a respiratory mucosa vaccine adjuvant.

The invention belongs to the technical field of biological medicine, and relates to a peptide protein kinase C inhibitor and application thereof, in particular to a protein kinase C zeta type novel inhibitor and application thereof as a tissue penetrating agent, especially in the background of cancer prevention and / or treatment or immune response induction, especially mucosal vaccination or anti-opioid drug treatment. The inhibitors are peptides having a total of 5 to 10 amino acids of the structure of formula (I), advantageously useful for inducing transient tissue penetration, in particular for enhancing penetration of large therapeutic molecules, for transmucosal delivery of high molecular weight drugs, avoiding parenteral administration of such drugs.

Embodiments of the present disclosure pertain to a composition that includes a particle, an antigen, and a modulator. The modulator may include, without limitation, an agonist, an activator of the immune system, or combinations thereof. The antigen may be operable to elicit an immune response in a subject against respiratory syncytial virus (RSV). Additional embodiments of the present disclosure pertain to methods of treating or preventing a respiratory infection in a subject by administering a composition of the present disclosure to the subject.

Methods for stabilizing a liquid vaccine for mucosal use are provided. In certain aspects, the methods may include combining a liquid comprising at least one antigen or antigen encoding composition with a petrolatum carrier.

A non-infections bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.

A method of producing an immunotherapeutic mucosal cancer vaccine which is orally administered includes amplifying and synthesizing a cancer proliferating cell nuclear antigen (caPCNA); fusing enzymatically the caPCNA with an anchoring domain gene to produce a fusion gene; cloning the fusion gene into an expression vector; transforming the expression vector into Lactococcus lactis (L. lactis) cells to produce a transformant; harvesting the transformant; and encapsulating the transformant. The transformant exhibits display of the caPCNA on the cell surface of L. lactis. An immunotherapeutic mucosal vaccine composition contains the orally administered vaccine to treat various types of cancer that are positive to the tumor antigen, caPCNA. A method of immunotherapy for a mucosal vaccine to treat cancer includes orally administering to a subject an amount of the immunotherapeutic mucosal vaccine composition. The immunotherapy composition triggers targeted killing of cancer cells by stimulating immune cells to treat various cancers.

This invention relates to the field of biopharmaceutical technology, specifically to a recombinant pentamer protein, polynucleotide, expression vector, host cell, preparation method, and application. The fusion protein is formed by fusing LTB or its immunogenic functional variant with the pentamer domain of COMP via a flexible linker peptide. This invention constructs the gene of this fusion protein in a eukaryotic expression vector, transfects it into CHO-K1 cells, obtains stable high-expression cell lines through pressure selection, and performs efficient secretory expression using serum-free suspension culture. The resulting protein forms a pentamer under non-reducing conditions. The sIgA level in mouse nasal lavage fluid is significantly higher than that of the antigen alone, confirming its effective activation of local immunity in the respiratory mucosa. This invention utilizes the CHO expression system to achieve large-scale preparation of structurally correct, homogeneous, and endotoxin-free LTB pentamers, which has significant application value in the development of mucosal vaccines, targeted delivery, and diagnostic reagents.

The invention discloses a chitosan-modified manganese polyoxide nano-enzyme adjuvant, a preparation method and application of the chitosan-modified manganese polyoxide nano-enzyme adjuvant in preparation of influenza mucosal vaccines, and belongs to the technical field of biomedicines.The preparation method comprises the steps that KMnO4, oleic acid, chitosan and the like serve as raw materials, CS is modified to the surface of MnOx through a rapid aqueous phase method, and the chitosan-modified manganese polyoxide nano-enzyme adjuvant is obtained; a novel mucosal immunologic adjuvant (chitosan-modified manganese polyoxide nano-enzyme adjuvant) is synthesized and successfully applied to influenza virus mucosal vaccines, the adhesion ability of inactivated viruses in nasal mucosa can be remarkably enhanced, the antigen exposure time can be prolonged, and the recruitment of DCs below the mucosa can be enhanced. Animal experiments show that the influenza mucosal vaccine containing the CS-MnOx adjuvant can increase the survival rate of mice after challenge to 100% (the survival rate of a control group is only 20%), and weight loss caused by viruses is effectively relieved. The adjuvant technology can be expanded to the development of other respiratory pathogen vaccines, and a new strategy is provided for the design of mucosal immune vaccines.